Posts

Pharma industry news Symeres acquires DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Image
  Unsorted Symeres, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announces the acquisition of DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients. The acquisition is supported by Keensight Capital (“Keensight”), one of the leading private equity managers dedicated to pan-European Growth Buyout[[1]] investments. Founded in 2018 and based in the Netherlands, DGr Pharma specialises in pre-clinical and clinical regulatory strategy and consultancy for biotech and pharmaceutical partners working in early drug development. Its core services include chemical-pharmaceutical, non-clinical and clinical development planning, quality assurance, and regulatory submissions. DGr Pharma has deep expertise in small and large molecules including antibodies, ADCs and oligonucleotides. With a reputation for scientific rigor, DGr Pharma ...
Post a Comment
Read more

Edward Bartles on Future of Clinical Trials: IQVIA

Image
  The Future of Clinical Trials: Integrating Technology and patient Experience In this engaging interview, Edward Bartles, Associate Director of Solution Engineering at IQVIA, discusses the impact of digital health technologies and wearables on the clinical trials landscape. The conversation covers IQVIA’s strategic approach to embedding digital tools in the research process—from electronic clinical outcome assessments (eCOA) and IoT platforms to global device sourcing and real-time data collection. Edward explains how adopting e-consenting, connected devices, and flexible trial design reduces patient burden and improves engagement across multi-region Phase III studies. https://www.youtube.com/watch?v=S0nhMq5eils&t=39s Special emphasis is given to regulatory trends, including decentralized trial implementation, EU clinical trials regulation, and the increasing flexibility behind trial methodology. The discussion highlights the importance of ensuring data quality, adaptability, ...
Post a Comment
Location: Hyderabad, Telangana, India
Read more

Latest Pharma News - Record international attendance at CPHI & PMEC China 2025

Image
Note* — All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. China’s biotech sector is now a key driver of innovation across global pipelines, as CPHI Shenzhen prepares for largest ever influx of foreign dealmakers Sino-international trade is accelerating as CPHI & PMEC China (June 24–26, 2025) reported a record-breaking international attendance, with a 30% year-on-year increase. The sharp uptick reflects surging demand from Western pharma, with China-based biotech in-licensing fuelling global pipelines, and wider partnering in China. Remarkably, international executives now account for nearly quarter of all visitors, with over 15,000 being international, led by rapid growth from Europe and the United States. Asia’s largest pharmaceutical event welcomed 109,056 attendees from 147 countries and 3,600 exhibitors across 240,000+ square meters, reinforcing its position as the largest and most globa...
Post a Comment
Read more

Rethinking Real-World Data Partnerships: How to Fill Gaps Without Starting Over

Image
  Noah Nasser, CEO of  datma Most pharmaceutical companies have already invested heavily in real-world data (RWD). These internal datasets, often curated over years, serve as the foundation for ongoing research and analysis. They often represent significant investment in time, budget, and coordination across internal teams and systems. But even robust internal datasets can fall short when new analytical needs or questions arise, particularly in the context of targeted therapies where biomarker specific insights are essential.  When a stakeholder asks a question about a subpopulation defined by a biomarker, mutation type, or clinical context, the existing dataset may not contain the patients needed to answer it. The missing data might be subtle, such as biomarker status or specific genomic features, but they are often essential. This doesn’t mean the internal dataset is flawed, it reflects the evolving nature of oncology and the reality that new questions often demand new ...
Post a Comment
Read more

Global healthcare AI experts and former UK Health Minister back AI that detects healthcare-associated infections up to 72 hours earlier

Image
  Sanome’s MEMORI becomes the first UK‑built, Certified Class IIb Software-as-a-Medical Device for real-time infection prediction, ahead of NHS rollout and FDA approval. AI tool that spots hospital infections up to 72 hours early, newly backed by former health minister Lord Bethell, Prof Carole Longson and Dr Arrash Yassaee Sanome’s MEMORI becomes the first UK-developed AI medical device that predicts and detects infections earlier, to achieve Class IIb Medical Device CE certification and MHRA approval The technology delivers real-time alerts to clinical teams with no disruption, helping ease pressure on overburdened hospitals, supporting the new NHS 10-Year Plan’s focus on prevention and early intervention Sanome, a company building Clinical Decision Support tools to detect emerging health risks, has secured Class IIb CE certification and MHRA approval for MEMORI – an AI-enabled warning system for the early prediction/prevention of healthcare‑associated infections (HAIs) – at the ...
Post a Comment
Location: Hyderabad, Telangana, India
Read more

Agilent and Tata Institute of Fundamental Research, Hyderabad collaborate to advance scientific frontiers in health and metabolism research

Image
  Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. In a significant step toward strengthening India’s efforts in nutrition and metabolism research, Agilent Technologies and the Tata Institute of Fundamental Research (TIFR), Hyderabad have announced a strategic collaboration to support ARUMDA (Advanced Research Unit on Metabolism, Development, and Aging). This partnership brings together Agilent’s global expertise in analytical science with TIFR’s research endeavors to address the growing burden of non-communicable diseases (NCDs) and malnutrition in the country. A key outcome of this collaboration is the launch of the Agilent–TIFR Center of Translational Research in Hyderabad. The center will play a pivotal role in supporting the Advanced Research Unit on Metabolism, Development & Aging (ARUMDA)—one of India’s most ambitious government-supported initiatives in human health. ARUM...
Post a Comment
Read more

Sino Biological Sets New Industry Standard with ProPure™ Endotoxin-Free Proteins Made in the USA

Image
  Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. Sino Biological US, Inc. proudly unveils  ProPure™ , an  industry-leading line of ultra-pure, endotoxin-free recombinant proteins ,  fully produced in the USA  at its state-of-the-art Center for Bioprocessing (C4B) facility in Houston, Texas. This new product line is specifically engineered to meet the rigorous demands of immunology research, vaccine development, animal studies, cell and gene therapy, and therapeutic protein manufacturing. The newly released proteins are manufactured using advanced purification and production technologies, ensuring endotoxin levels below the limit of quantification (LOQ). By leveraging mammalian expression systems and proprietary purification protocols, the C4B delivers high-purity proteins tailored for sensitive applications where even trace endotoxin contamination can comp...
Post a Comment
Location: India
Read more